Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00916747|
Recruitment Status : Enrolling by invitation
First Posted : June 9, 2009
Last Update Posted : April 10, 2018
Boston Children’s Hospital
Information provided by (Responsible Party):
Monica E. Kleinman, Boston Children's Hospital
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Enrolling by invitation|
|Estimated Primary Completion Date :||June 2018|
|Estimated Study Completion Date :||June 2018|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Gordon LB, Kleinman ME, Massaro J, D'Agostino RB Sr, Shappell H, Gerhard-Herman M, Smoot LB, Gordon CM, Cleveland RH, Nazarian A, Snyder BD, Ullrich NJ, Silvera VM, Liang MG, Quinn N, Miller DT, Huh SY, Dowton AA, Littlefield K, Greer MM, Kieran MW. Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome. Circulation. 2016 Jul 12;134(2):114-25. doi: 10.1161/CIRCULATIONAHA.116.022188.
Gordon LB, Massaro J, D'Agostino RB Sr, Campbell SE, Brazier J, Brown WT, Kleinman ME, Kieran MW; Progeria Clinical Trials Collaborative. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. Circulation. 2014 Jul 1;130(1):27-34. doi: 10.1161/CIRCULATIONAHA.113.008285. Epub 2014 May 2.